Plasma Pharmacokinetics of High-Dose Oral versus Intravenous Rifampicin in Patients with Tuberculous Meningitis: a Randomized Controlled Trial-Reference-Cited by-同舟云学术

Plasma Pharmacokinetics of High-Dose Oral versus Intravenous Rifampicin in Patients with Tuberculous Meningitis: a Randomized Controlled Trial

Published:2021-07-16 Issue:8 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Wasserman Sean¹²^ORCID,Davis Angharad¹³⁴,Stek Cari¹⁵⁶,Chirehwa Maxwell⁷,Botha Stephani¹,Daroowala Remy¹⁵,Bremer Marise¹⁸,Maxebengula Mpumi¹,Koekemoer Sonya¹,Goliath Rene¹,Jackson Amanda¹,Crede Thomas⁶⁹,Naude Jonathan⁶⁹,Szymanski Patryk⁶⁹,Vallie Yakoob⁶¹⁰,Moosa Muhammed S.⁶¹⁰,Wiesner Lubbe⁷^ORCID,Black John⁸,Meintjes Graeme¹²,Maartens Gary¹⁷^ORCID,Wilkinson Robert J.¹²³⁴⁵

Affiliation:

1. Wellcome Centre for Infectious Diseases Research in Africa, Institute for Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa

2. Division of Infectious Diseases and HIV Medicine, Department of Medicine, University of Cape Town, Cape Town, South Africa

3. Francis Crick Institute, London, United Kingdom

4. Faculty of Life Sciences, University College London, London, United Kingdom

5. Department of Infectious Diseases, Imperial College, London, United Kingdom

6. Department of Medicine, University of Cape Town, Cape Town, South Africa

7. Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa

8. Livingstone Hospital Complex, Eastern Cape Department of Health, Port Elizabeth, South Africa

9. Mitchells Plain Hospital, Western Cape Department of Health, Cape Town, South Africa

10. New Somerset Hospital, Western Cape Department of Health, Cape Town, South Africa

Abstract

Higher doses of intravenous rifampicin may improve outcomes in tuberculous meningitis but are impractical in high-burden settings. We hypothesized that plasma rifampicin exposures would be similar between oral dosing of 35 mg/kg of body weight and intravenous dosing of 20 mg/kg, which has been proposed for efficacy trials in tuberculous meningitis.

Funder

National Research Foundation of South Africa

Meningitis Now

HHS | National Institutes of Health

UK Research and Innovation

Wellcome Trust

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00140-21